menu
    • menu
    [{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Alzheimer's Drug Discovery Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Alzheimer's Drug Discovery Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Alzheimer's Drug Discovery Foundation"},{"orgOrder":0,"company":"Adtech Pharma","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Adtech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Adtech Pharma \/ Ault Global Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Adtech Pharma \/ Ault Global Holdings"}]

    Find Clinical Drug Pipeline Developments & Deals for Nabilone

    Menu

    Nabilone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Centre for Addiction and Mental Health

                            Country arrow
                            FNCE
                            Not Confirmed

                            Centre for Addiction and Mental Health

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigating the Effects of Nabilone on Endocannabinoid Metabolism

                            Details : Nabilone is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 02, 2023

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adtech Pharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Adtech Pharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Ault Global Holdings

                            Deal Size : $3.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ault Global Holdings Announces Agreement to Acquire up to 40% of Adtech Pharma, Inc.

                            Details : NB-110 comprises of a synthetic cannabinoid Nabilone in the absence of any preservative and its formulation mimics a human tear to drive efficacious delivery through the cornea to the retina and optical nerves in the back of eye.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            June 28, 2021

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Ault Global Holdings

                            Deal Size : $3.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Centre for Addiction and Mental Health

                            Country arrow
                            FNCE
                            Not Confirmed

                            Centre for Addiction and Mental Health

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pilot Trial of Nabilone for the Treatment of Obesity

                            Details : Nabilone is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 17, 2021

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            FNCE
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Alzheimer's Drug Discovery Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nabilone for Agitation Blinded Intervention Trial

                            Details : Nabilone is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 17, 2020

                            Lead Product(s) : Nabilone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Alzheimer's Drug Discovery Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth